Teva falls on Goldman downgrade

|About: Teva Pharmaceutical Industr... (TEVA)|By:, SA News Editor

Goldman downgrades Teva Pharmaceutical (TEVA -1.8%) to Sell, price target is $40.

The company's focus on pipeline rebuilding has left it "relatively quiet" in an environment "awash with accretive deal activity," analyst Jami Rubin notes.

Of course there's also the whole generic Copaxone problem which Rubin says will leave the company "facing fewer options with respect to capital allocation."

Previously: Patent invalidation dents TEVA's plan to transition Copaxone patients to longer-acting formulation.